Lombard Medical Inc (EVAR.OQ) Key Developments | Reuters.com
Edition:
United States

Analyst Research

Report Title Price
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Pechala's Reports
$25.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Lombard Medical Inc 's Aorfix receives regulatory approval in Japan for treatment of Abdominal Aortic Aneurysms


Tuesday, 5 Aug 2014 06:00am EDT 

Lombard Medical Inc:Announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from Japanese Ministry of Health, Labour and Welfare.Commercial sales will follow reimbursement approval, which the Company anticipates receiving in Sept.Aorfix will be exclusively distributed by Medico's Hirata Inc., one of Japan's suppliers of vascular products with proven expertise in building significant market share for AAA stent grafts.Japan is world's second largest, standalone EVAR market.Aorfix is the first and only endovascular stent graft approved in Japan to treat AAA in patients with aortic neck angulations up to 90 degrees, commonly considered to be challenging cases.Aorfix is currently approved to treat patients with neck angles up to 90 degrees in US and Europe. 

Company Quote

1.29
0.1 +8.40%
24 Jun 2016